Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

NCT01142401 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

118

Enrollment

NIH

Sponsor class

Conditions

Metastatic Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7

Interventions

DRUG: Bortezomib
DRUG: Fulvestrant
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)